SCHEMBL1427372

SCHEMBL1427372

CCN(CC)CCOc1cccc(C=O)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
TSHR P16473 1/20 0.58
MAOB P27338 6/20 0.54
MAOA P21397 5/20 0.54
BCHE P06276 2/20 0.54
ACHE P22303 2/20 0.54
MAPT P10636 1/20 0.52
CHRNA7 P36544 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.50
LTA4H P09960 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50
ESR1 P03372 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9364428 0.90 MAOB (0.54) KDM4ETSHRMAOBMAOABCHE
SCHEMBL29658517 0.84 CHRNB2 (0.59) KDM4EMAOBMAOABCHEACHE
SCHEMBL901802 0.84 CHRNB2 (0.59) KDM4EMAOBMAOABCHEACHE
SCHEMBL9706141 0.84 KDM4E (0.73) KDM4ETSHRMAOBMAPTCHRNA7
SCHEMBL910596 0.82 MAOA (0.58) KDM4ETSHRMAOBMAOAMAPT
SCHEMBL870305 0.82 CYP1A2 (0.61) MAOBBCHEACHEMAPTCHRNA7
SCHEMBL29955687 0.82 MAOA (0.58) KDM4ETSHRMAOBMAOAMAPT
SCHEMBL5543437 0.82 MAOA (0.66) MAOBMAOAKMT2ANPC1RAB9A
SCHEMBL30409096 0.81 TLR4 (0.64) TSHRMAOBMAOAMAPTKMT2A
Hydrochloric Acid SCHEMBL5692419 0.81 CYP1A2 (0.59) MAOBBCHEACHEMAPTCHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300440-B1 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-02-27 EP disclosed
US-20110124666-A1 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS Janssen Pharmaceutica NV a corporation 2011-05-26 US disclosed
EP-2300440-A1 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2011-03-30 EP disclosed
WO-2009147079-A1 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2009-12-10 WO disclosed
US-RE39708-E1 Estrogen receptor modulators CHIRON CORPORATION (US) 2007-06-26 US disclosed
EP-1102753-B1 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS NOVARTIS VACCINES & DIAGNOSTIC (US) 2007-02-28 EP disclosed
US-6869969-B2 Estrogen receptor modulators CHIRON CORPORATION (US) 2005-03-22 US disclosed
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same HUSSON HENRI-PHILIPPE (FR) 2004-09-16 US disclosed
US-6743815-B2 OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE CHIRON CORPORATION 2004-06-01 US disclosed
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors CHIRON CORPORATION 2004-05-27 US disclosed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 US disclosed
EP-1102753-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2001-05-30 EP disclosed
EP-1102755-A1 SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2001-05-30 EP disclosed
WO-2000007996-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2000-02-17 WO disclosed
WO-2000008001-A1 SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2000-02-17 WO disclosed
US-4478598-A FOR TEXTILES AND IN LAUNDRY DETERGENTS CIBA-GEIGY CORPORATION (US) 1984-10-23 US disclosed
US-4336374-A HYPOGLYCEMIC AGENTS NIPPON SHINYAKU CO., LTD. (JP) 1982-06-22 US disclosed
US-4053514-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1977-10-11 US disclosed
US-4038274-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1977-07-26 US disclosed
US-3969527-A INDENO(1,2-C)PYRAZOLE E. R. SQUIBB & SONS, INC. (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same SCN11A, CYP4A11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KDM4E 4257/4885TSHR 2272/4885MAOB 569/4885
US-20110124666-A1 3,4-DIHYDROPYRIMIDINE TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV3 KDM4E 4538/4885TSHR 2309/4885MAOB 3054/4885
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors ESR2, GPER1, ESR1 KDM4E 3177/4885TSHR 557/4885MAOB 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.